Kazia Therapeutics Past Earnings Performance
Past criteria checks 0/6
Kazia Therapeutics's earnings have been declining at an average annual rate of -18.6%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been declining at an average rate of 12.3% per year.
Key information
-18.6%
Earnings growth rate
9.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -12.3% |
| Return on equity | n/a |
| Net Margin | -1,079.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy
Jul 06Kazia enters clinical collaboration with Cornell University for mid-stage glioblastoma trial
Jun 15Enrollment gets underway in Kazia's mid-stage lymphoma study
Jun 07Kazia, Pacific Pediatric Neuro-Oncology collaborate for paxalisib combo study in type of brain cancer
Dec 10Kazia Therapeutics -2% on cantrixil data in early-stage ovarian cancer study
Dec 09Kazia stock +22% on positive paxalisib data in glioblastoma
Nov 18Revenue & Expenses Breakdown
How Kazia Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -27 | 14 | 17 |
| 31 Mar 24 | 1 | -21 | 11 | 14 |
| 31 Dec 23 | 0 | -16 | 9 | 11 |
| 30 Sep 23 | 0 | -18 | 9 | 13 |
| 30 Jun 23 | 0 | -20 | 9 | 16 |
| 31 Mar 23 | 0 | -23 | 8 | 17 |
| 31 Dec 22 | 0 | -25 | 7 | 19 |
| 30 Sep 22 | 0 | -25 | 6 | 19 |
| 30 Jun 22 | 0 | -25 | 5 | 20 |
| 31 Mar 22 | 8 | -20 | 5 | 21 |
| 31 Dec 21 | 15 | -15 | 6 | 23 |
| 30 Sep 21 | 15 | -12 | 6 | 19 |
| 30 Jun 21 | 15 | -8 | 7 | 15 |
| 31 Mar 21 | 8 | -11 | 6 | 11 |
| 31 Dec 20 | 0 | -13 | 5 | 8 |
| 30 Sep 20 | 1 | -13 | 4 | 9 |
| 30 Jun 20 | 1 | -12 | 4 | 9 |
| 31 Mar 20 | 1 | -11 | 4 | 8 |
| 31 Dec 19 | 1 | -10 | 4 | 7 |
| 30 Sep 19 | 1 | -10 | 4 | 7 |
| 30 Jun 19 | 1 | -10 | 4 | 6 |
| 31 Mar 19 | 2 | -11 | 4 | 8 |
| 31 Dec 18 | 2 | -12 | 3 | 9 |
| 30 Sep 18 | 3 | -9 | 4 | 9 |
| 30 Jun 18 | 3 | -6 | 6 | 10 |
| 31 Mar 18 | 4 | -6 | 7 | 10 |
| 31 Dec 17 | 6 | -6 | 9 | 11 |
| 30 Sep 17 | 7 | -8 | 9 | 11 |
| 30 Jun 17 | 9 | -11 | 9 | 11 |
| 31 Mar 17 | 7 | -12 | 8 | 10 |
| 31 Dec 16 | 5 | -12 | 7 | 10 |
| 30 Sep 16 | 4 | -12 | 6 | 10 |
| 30 Jun 16 | 3 | -12 | 6 | 10 |
| 31 Mar 16 | 3 | -10 | 6 | 9 |
| 31 Dec 15 | 3 | -9 | 5 | 8 |
| 30 Sep 15 | 2 | -8 | 5 | 7 |
| 30 Jun 15 | 2 | -7 | 4 | 6 |
| 31 Mar 15 | 2 | -7 | 3 | 6 |
| 31 Dec 14 | 2 | -7 | 3 | 5 |
| 30 Sep 14 | 1 | -7 | 3 | 4 |
| 30 Jun 14 | 0 | -7 | 3 | 3 |
| 31 Mar 14 | 0 | -6 | 3 | 2 |
| 31 Dec 13 | 1 | -5 | 3 | 1 |
Quality Earnings: KZIA is currently unprofitable.
Growing Profit Margin: KZIA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KZIA is unprofitable, and losses have increased over the past 5 years at a rate of 18.6% per year.
Accelerating Growth: Unable to compare KZIA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KZIA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: KZIA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 02:58 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kazia Therapeutics Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Soo Romanoff | Edison Investment Research |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |